SLDB Valuation

Solid Biosciences Inc

Add to Watchlist

Advanced Chart

6.030

-0.08(-1.309%)1D

Overview
Forecast
Valuation
Earnings

SLDB Relative Valuation

SLDB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SLDB is overvalued; if below, it's undervalued.

Historical Valuation

Solid Biosciences Inc (SLDB) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.78. The fair price of Solid Biosciences Inc (SLDB) is between NaN to NaN according to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：6.18

Fair

-3.18

Trailing

Forward

-1.30

EV/EBITDA

Solid Biosciences Inc. (SLDB) has a current EV/EBITDA of -1.30. The 5-year average EV/EBITDA is -0.72. The thresholds are as follows: Strongly Undervalued below -3.38, Undervalued between -3.38 and -2.05, Fairly Valued between 0.61 and -2.05, Overvalued between 0.61 and 1.94, and Strongly Overvalued above 1.94. The current Forward EV/EBITDA of -1.30 falls within the Historic Trend Line -Fairly Valued range.

-1.32

EV/EBIT

Solid Biosciences Inc. (SLDB) has a current EV/EBIT of -1.32. The 5-year average EV/EBIT is -0.74. The thresholds are as follows: Strongly Undervalued below -4.60, Undervalued between -4.60 and -2.67, Fairly Valued between 1.18 and -2.67, Overvalued between 1.18 and 3.11, and Strongly Overvalued above 3.11. The current Forward EV/EBIT of -1.32 falls within the Historic Trend Line -Fairly Valued range.

0.00

Solid Biosciences Inc. (SLDB) has a current PS of 0.00. The 5-year average PS is 29.33. The thresholds are as follows: Strongly Undervalued below -66.00, Undervalued between -66.00 and -18.34, Fairly Valued between 76.99 and -18.34, Overvalued between 76.99 and 124.66, and Strongly Overvalued above 124.66. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-3.00

P/OCF

Solid Biosciences Inc. (SLDB) has a current P/OCF of -3.00. The 5-year average P/OCF is -3.11. The thresholds are as follows: Strongly Undervalued below -8.13, Undervalued between -8.13 and -5.62, Fairly Valued between -0.60 and -5.62, Overvalued between -0.60 and 1.92, and Strongly Overvalued above 1.92. The current Forward P/OCF of -3.00 falls within the Historic Trend Line -Fairly Valued range.

-3.09

P/FCF

Solid Biosciences Inc. (SLDB) has a current P/FCF of -3.09. The 5-year average P/FCF is -2.93. The thresholds are as follows: Strongly Undervalued below -7.73, Undervalued between -7.73 and -5.33, Fairly Valued between -0.53 and -5.33, Overvalued between -0.53 and 1.88, and Strongly Overvalued above 1.88. The current Forward P/FCF of -3.09 falls within the Historic Trend Line -Fairly Valued range.

Solid Biosciences Inc (SLDB) has a current Price-to-Book (P/B) ratio of 1.84. Compared to its 3-year average P/B ratio of 0.96 , the current P/B ratio is approximately 91.93% higher. Relative to its 5-year average P/B ratio of 1.59, the current P/B ratio is about 15.52% higher. Solid Biosciences Inc (SLDB) has a Forward Free Cash Flow (FCF) yield of approximately -25.67%. Compared to its 3-year average FCF yield of -81.25%, the current FCF yield is approximately -68.40% lower. Relative to its 5-year average FCF yield of -67.41% , the current FCF yield is about -61.92% lower.

1.84

P/B

Median3y

0.96

Median5y

1.59

-25.92

FCF Yield

Median3y

-81.25

Median5y

-67.41

Competitors Valuation Multiple

The average P/S ratio for SLDB's competitors is 7.79, providing a benchmark for relative valuation. Solid Biosciences Inc Corp (SLDB) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

SLDB.O

Solid Biosciences Inc

Autolus Therapeutics PLC

Iteos Therapeutics Inc

Performance Decomposition

Market capitalization of SLDB increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of SLDB in the past 1 year is driven by Unknown.